Reslizumab in the management of poorly controlled asthma: the data so far.

J Asthma Allergy · 2016 · PMC5012840 · PMID 27621657

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The primary outcome – Asthma Control Questionnaire (ACQ) scores – showed a trend favoring better asthma control in the reslizumab group (−0.7 vs −0.3), but was not considered statistically significant ( P =0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.